=> d his

(FILE 'HOME' ENTERED AT 14:05:18 ON 28 AUG 2003)

FILE 'REGISTRY' ENTERED AT 14:05:25 ON 28 AUG 2003
L1 1 S 287714-41-4/RN This is the (E)-7- etc compd.

FILE 'HCAPLUS' ENTERED AT 14:05:56 ON 28 AUG 2003
L2 100 S L1 100 hits for
L3 73 S L2 AND (?THERAP? OR ?PHARM?) 73 hits when combined with therap or pharm
L4 0 S L3 AND PRD<199902 0 hits before Feb 99 (priority date)
L5 0 S L3 AND PD<19990201 0 hits before Feb 99 (pub date)

FILE 'REGISTRY' ENTERED AT 14:14:30 ON 28 AUG 2003
E FENOFIBRATE/CN
L6 1 S E3
L7 0 S L1 AND (L6 OR ?FENOFIBRATE?)

FILE 'HCAPLUS' ENTERED AT 14:15:34 ON 28 AUG 2003
L8 17 S L1 AND (L6 OR ?FENOFIBRATE?)) same search as earlier one
L9 15 S L8 AND (?THERAP? OR ?PHARM?)) so I could get the 2 addnl. cits.
L10 2 S L8 NOT L9 .
L11 806 S L6 OR ?FENOFIBRATE? 806 cits for fenofibrate
L12 370 S L11 AND (?THERAP? OR ?PHARM?) 370 when combined with therap or pharm
L13 143 S L12 AND PD<19990201 143 cits before Feb 99 (priority date)
L14 57 S L12 AND PRD<19990201 57 cits " " " (pub date

=> d ibib abs hitstr hitrn l10 1-2

L10 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:927185 HCAPLUS
DOCUMENT NUMBER: 138:24716
TITLE: Preparation of azolecarboxylic acids useful as antidiabetic and antiobesity agents
INVENTOR(S): Cheng, Peter T.; Zhang, Hao; Hariharan, Narayanan
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096358	A2	20021205	WO 2002-US16633	20020523
WO 2002096358	A3	20030327		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-294380P P 20010530
OTHER SOURCE(S): MARPAT 138:24716
GI



I



II

AB Title compds. [I; m, n = 0-2; Q = C, N; A = (CH2)x, (CH2)x1, (CH2)x2O(CH2)x3; x = 1-5; x1 = 2-5; x2, x3 = 0-5; .gtoreq.1 of x2, x3 .noteq. 0; X1 = CH, N; X2, X3, X4, X5, X7 = C, N, O, S; in each of X1-X7, C may include CH; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, (substituted) amino; R2a, R2b and R2c = H, alkyl, alkoxy, halo, (substituted) amino; R3, R3a = H, alkyl, arylalkyl, aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, alkyl(halo)aryloxycarbonyl, alkoxy(halo)aryloxycarbonyl, cycloalkylaryloxycarbonyl, cycloalkyloxyaryloxycarbonyl, cycloheteroalkyl, heteroarylcarbonyl, heteroarylheteroarylalkyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, heteroarylheteroarylcarbonyl, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, heteroarylalkyl, aminocarbonyl, substituted aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aryloxyarylalkyl, alkynyloxycarbonyl, haloalkoxyaryloxycarbonyl, alkoxycarbonylaryloxycarbonyl, aryloxyaryloxycarbonyl, arylsulfinylarylcarbonyl, etc.; Y = CO2R4, 1-tetrazolyl, P(O)(OR4a)R5, P(O)(OR4a)2; R4 = H, alkyl, prodrug ester; R4a = H, prodrug ester; R5 = alkyl, aryl; with provisos], were prepd. as simultaneous inhibitors of peroxisome proliferator activated receptor-.gamma. (PPAR.gamma.) and stimulators of peroxisome proliferator activated receptor-.alpha. (PPAR.alpha.). Thus, title compd. (II) (prepd. starting from Meldrum's acid 3-methoxyphenylacetyl chloride) bound to human PPAR.alpha. and to PPAR.gamma. ligand binding domains with IC50 = 69 nM.

IT **49562-28-9, Fenofibrate 287714-41-4**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; prepn. of azolecarboxylic acids useful as antidiabetic and antiobesity agents)

RN 49562-28-9 HCAPLUS

CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 287714-41-4 HCAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **49562-28-9, Fenofibrate 287714-41-4**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; prepn. of azolecarboxylic acids useful as antidiabetic and antiobesity agents)

L10 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:927184 HCAPLUS
DOCUMENT NUMBER: 138:14048
TITLE: Preparation of oxazolylethoxyphenylprolines and related compounds as antidiabetic and antiobesity agents.
INVENTOR(S): Cheng, Peter T.; Jeon, Yoon; Wang, Wei
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096357	A2	20021205	WO 2002-US16628	20020523
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003092697	A1	20030515	US 2002-153342	20020522

PRIORITY APPLN. INFO.: US 2001-294505P P 20010530
OTHER SOURCE(S): MARPAT 138:14048
GI



I



II

AB Title compds. [I; m, n = 0-2; Q = C, N; A = (CH2)x, (CH2)x1, with an alkenyl or alkynyl bond in the chain, (CH2)x2O(CH2)x3; x = 1-5; x1 = 2-5; x2, x3 = 0-5; provided that .gtoreq.1 of x2 and x3 .noteq. 0; X1 = CH, N; X2 = C, N, O, S; X3 = C, N; X4 = C, N, O, S provided that .gtoreq.1 of X2, X3, X4 = N; in each of X1-X4, C may include CH; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, (substituted) amino; R2a, R2b R2c = H, alkyl, alkoxy, halo, (substituted) amino; R3 = H, alkyl, arylalkyl, aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, cycloheteroalkyl, heteroarylcarbonyl, heteroarylheteroarylalkyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, heteroarylheteroarylcarbonyl, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, aryloxyheteroarylalkyl, heteroarylalkyloxyarylalkyl, arylarylalkyl, arylalkenylarylalkyl, arylaminoarylalkyl, etc.; Y = CO2R4, 1-tetrazolyl, P(O)(OR4a)R5, P(O)(OR4a)2; R4 = H, alkyl, prodrug ester; R4a = H, prodrug ester; R5 = alkyl, aryl; Z = (CH2)x4, (CH2)x5, (CH2)x6O(CH2)x7; x4 = 1-5; x5 = 2-5; x6, x7 = 0-4], were prepd. as antidiabetic and antiobesity agents (no data). Thus, title compd. (II) was prepd. in 6 steps.

IT **49562-28-9, Fenofibrate 287714-41-4**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; prepn. of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)

RN 49562-28-9 HCAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 287714-41-4 HCAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-

[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **49562-28-9, Fenofibrate 287714-41-4**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; prepn. of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)